AC
ACRS icon

Aldebaran Capital’s Aclaris Therapeutics ACRS Stock Holding History

Aldebaran Capital’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.55M Sell
947,162
-7,100
-0.7% -$24K 2.72% 11
2025
Q4 		$2.87M Sell
954,262
-33,436
-3% -$84.5K 2.58% 12
2025
Q3 		$1.88M Sell
987,698
-6,000
-0.6% -$10.5K 1.72% 18
2025
Q2 		$1.41M Sell
993,698
-14,260
-1% -$19.3K 1.39% 18
2025
Q1 		$1.54M Sell
1,007,958
-9,000
-0.9% -$19.2K 1.46% 19
2024
Q4 		$2.52M Sell
1,016,958
-26,194
-3% -$65.2K 2.4% 13
2024
Q3 		$1.2M Buy
1,043,152
+185,000
+22% +$227K 1.1% 20
2024
Q2 		$944K Buy
+858,152
New +$1.01M 0.88% 21

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Aldebaran Capital's ACRS Position: Q1 2026 in Review

Aldebaran Capital reduced its Aclaris Therapeutics (ACRS) stake by 0.74% in Q1 2026, selling an estimated $24K and leaving 947,162 shares worth $3.55M. The position accounts for 2.72% of the portfolio, ranked #11.

Aldebaran Capital first reported a position in ACRS in Q2 2024 and has held it in 8 quarters since. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Aldebaran Capital held 947,162 shares of Aclaris Therapeutics worth $3.55M as of Q1 2026.
  • Aldebaran Capital sold 7,100 Aclaris Therapeutics shares in Q1 2026, an estimated $24K.
  • Aclaris Therapeutics made up 2.72% of Aldebaran Capital's portfolio in Q1 2026, its #11 holding.
  • Aldebaran Capital first reported a position in Aclaris Therapeutics in Q2 2024 and has held it in 8 quarters since.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Aldebaran Capital's 13F filing for Q1 2026, filed 7 May 2026.